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Available online 27 February 2016Direct conversion of ﬁbroblasts into induced cardiomyocytes (iCMs) offers an alternative strategy for cardiac dis-
ease modeling and regeneration. During iCM reprogramming, the starting ﬁbroblasts must overcome existing
epigenetic barriers to acquire the CM-like chromatin pattern. However, epigenetic dynamics along this
reprogramming process have not been studied. Here, we took advantage of our recently generated polycistronic
system and determined the dynamics of two critical histone marks, H3K27me3 and H3K4me3, in parallel with
gene expression at a set of carefully selected cardiac and ﬁbroblast loci during iCM reprogramming.We observed
reduced H3K27me3 and increased H3K4me3 at cardiac promoters as early as day 3, paralleled by a rapid signif-
icant increase in their mRNA expression. In contrast, H3K27me3 at loci encoding ﬁbroblast marker genes did not
increase until day 10 and H3K4me3 progressively decreased along the reprogramming process; these changes
were accompanied by a gradual decrease in the mRNA expression of ﬁbroblast marker genes. Further analyses
of ﬁbroblast-enriched transcription factors revealed a similarly late deposition of H3K27me3 and decreased
mRNA expression of Sox9, Twist1 and Twist2, three important players in epithelial−mesenchymal transition.
Our data suggest early rapid activation of the cardiac program and later progressive suppression of ﬁbroblast
fate at both epigenetic and transcriptional levels. Additionally, we determined the DNA methylation states of
representative cardiac promoters and found that not every single CpG was equally demethylated during early
stages of iCM reprogramming. Rather, there are speciﬁc CpGs, whose demethylation states correlated tightly
with transcription activation, that we propose are themajor contributing CpGs. Our work thus reveals a differen-
tial re-patterning of H3K27me3, H3K4me3 at cardiac and ﬁbroblast loci during iCM reprogramming and could
provide future genome-wide epigenetic studies with important guidance such as the appropriate time window
and loci to be utilized as positive and negative controls.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Direct conversion of ﬁbroblasts into a range of cell lineages (Huang
et al., 2011; Ieda et al., 2010; Szabo et al., 2010; Vierbuchen et al.,
2010) holds great potential for applications in disease modeling and
regenerative medicine. In the heart speciﬁcally, direct cardiac
reprogramming of ﬁbroblasts into induced cardiomyocytes (iCMs) has
been achieved in vitro and in vivo through several methods using the
transcription factor (TF) cocktail Gata4 (G), Mef2c (M), and Tbx5
(T) (Ieda et al., 2010; Inagawa et al., 2012; Qian et al., 2013; Qian
et al., 2012), a microRNA cocktail (Jayawardena et al., 2012), and other
variations (Nam et al., 2014; Song et al., 2012; Addis et al., 2013;
Christoforou et al., 2013; Ifkovits et al., 2014; Mathison et al., 2012;Building, 111 Mason Farm Rd,
d States.
. This is an open access article underMuraoka et al., 2014; Protze et al., 2012). Despite many attempts to im-
prove the efﬁciency of direct cardiac reprogramming (Addis et al., 2013;
Christoforou et al., 2013; Ifkovits et al., 2014; Mathison et al., 2012;
Muraoka et al., 2014; Protze et al., 2012), the conversion rate is still far
from the criteria for application. More importantly, across all these
different methods, only a fraction of cells expressing reprogramming
factors achieved a mature and functional cardiomyocyte (CM) state,
while many appeared at various stages of incomplete reprogramming.
This asynchronous conversion suggests the existence of a series of mo-
lecular barriers, such as the epigenetic barrier that must be overcome
during reprogramming in order for cells to acquire complete and stable
cell fate changes.
Cell reprogramming is inherently an epigenetic process (Theunissen
and Jaenisch, 2014). Heritable modiﬁcations to cytosine bases in the
DNA and histones that package the genome constitute the epigenome
(Bernstein et al., 2007). The epigenetic status of a cell regulates its chro-
matin structure and DNA accessibility, and inﬂuences expression of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and disease states. Consequently, cell fate changes such as those that
occur during normal development and cell reprogramming involve
dynamic re-patterning of epigenetic landscapes. Existing epigenetic
barriers in the starting cell type must be overcome and target cell-like
chromatin pattern must be built. Since the discovery of induced plurip-
otent stem cells (iPSC) (Takahashi and Yamanaka, 2006), epigenetic
remodeling along the process of reprogramming somatic cells to
pluripotency has been extensively characterized. Early and widespread
epigenetic re-patterning was observed and shown to be critical for
pluripotency induction (Buganim et al., 2013; Papp and Plath, 2013).
These studies not only improved our understanding of the molecular
mechanisms of induced pluripotency and addressed fundamental
questions about cell fate decisions, but also enabled rational design of
novel reprogramming cocktails. Similarly, elucidating the epigenetic
dynamics accompanying direct cardiac reprogramming is critical to
improve the efﬁciency and quality of iCM generation and to better our
understanding of the biology of ﬁbroblast plasticity and CM fate
determination.
Among the more than 100 different histone modiﬁcations,
histone3–lysine27–trimethylation (H3K27me3) and histone3–ly-
sine4–trimethylation (H3K4me3) are widely used histone marks
associated with inactive and active promoters, respectively (Zhou
et al., 2011). The H3K27me3 methyltransferase polycomb repressive
complex 2 is an important regulator of normal heart development (He
et al., 2012a; Delgado-Olguin et al., 2012). Mutations in MLL2, one of
the H3K4 methyltransferases, are a major cause of congenital heart
defects in Kabuki Syndrome in human (Ng et al., 2010). Recently, two
epigenetic studies on embryonic stem cell (ESC) differentiation into
CMs revealed distinct temporal patterns of H3K27me3 and H3K4me3
that are coordinated with changes in mRNA expression of functionally
related genes (Wamstad et al., 2012; Paige et al., 2012). Another impor-
tant regulator of chromatin state is the methylation status of CpG dinu-
cleotides in DNA, particularly in the promoter regions (Suzuki and Bird,
2008). Global lack of DNAmethylation in ESCs precludes differentiation
(Jackson et al., 2004) while DNAmethylation-silencing of pluripotency-
associated promoters allows differentiation to proceed (Feldman et al.,
2006). Dynamic DNAmethylation is also associatedwith normal cardiac
development, such as myocyte maturation and contractile functioning
during postnatal transition of CMs to mature adult CMs (Gilsbach
et al., 2014). Together, epigenetic regulation plays an essential role in
a variety of important cellular processes like cardiac development, yet
its role in direct cardiac reprogramming remains unknown.
Recently, we established a selectable polycistronic system for thede-
livery of iCM reprogramming factors G, M, and T, where the complete
set of constructs resulted in awide range of reprogramming efﬁciencies,
while infection with each construct led to a relatively homogenous cell
population (Wang et al., 2015). Since these constructs consistently give
rise to differential reprogramming consequences, parallel comparisons
among them may reveal important epigenetic changes and identify
key regulators and events in iCM reprogramming. In this study, we
ﬁrst characterized H3K27me3 and H3K4me3 patterns in primary
neonatal CMs, theHL-1 CM cell line, and three different types of primary
ﬁbroblasts to determine their levels at cardiac and ﬁbroblast loci in the
starting and target cell types of iCM reprogramming. Interestingly, our
data revealed that both H3K27me3 and H3K4me3 marks were present
at ﬁbroblast regulatory loci in CMs and at cardiac and ﬁbroblast regula-
tory loci in ﬁbroblasts.We then harnessed our polycistronic system and
utilized chromatin immunoprecipitation followed by quantitative PCR
(ChIP-qPCR) to interrogate cardiac andﬁbroblast promoters for possible
H3K27me3 and H3K4me3 re-patterning at two critical time points
during iCM reprogramming, and also sought to answer whether and
how observed changes in histone marks corresponded to mRNA
expression of these genes and reprogramming outcomes. Our data
revealed early changes in both histone marks at cardiac promoters
and later alterations at ﬁbroblast marker genes. This re-patterning ofhistone marks coincided with rapid activation of cardiac gene expres-
sion and gradual suppression of ﬁbroblast marker genes expression.
Next,we generated a list for ﬁbroblast-enriched TFs based on previously
published data and examined changes in histone marks at their
promoters during iCM reprogramming. We also found a late deposition
of H3K27me3 in about one third of the tested ﬁbroblast-enriched TFs,
and observed a decrease in mRNA expression in a few of these TFs.
Additionally, we determined the DNA methylation states of two select
cardiac loci and found that both promoters were demethylated at an
early stage of reprogramming. Importantly, we discovered that speciﬁc
CpGs in these promoters weremain contributors to total demethylation
and their methylation states closely correlated with transcription
activation.
2. Materials and methods
2.1. Mouse lines
Transgenic mice harboring GFP under the control of the αMHC
promoter (Ieda et al., 2010; Qian et al., 2013; Wang et al., 2015) were
used for primary neonatal CM, primary cardiac ﬁbroblast (CF), tail-tip
ﬁbroblast (TTF), and mouse embryonic ﬁbroblast (MEF) isolation.
Animal care was provided in accordance with guidelines established
by University of North Carolina, Chapel Hill.
2.2. Plasmids
The six polycistronic constructs expressingM, G, and T (pMXs-MGT/
MTG/TMG/TGM/GMT/GTM) and MGT with puro selection marker
(pMXs-puro-MGT) were previously constructed in the lab (Wang
et al., 2015). To generate pMXs-puro-GTM/DsRed, GTM was excised
from pGEMT-easy vector and DsRed was excised from pMXs-DsRed
(Addgene 22,724) and cloned into pMXs-puro vector. To generate
pMXs-GFP-Gata4-Tbx5, EGFP was PCR ampliﬁed from pLenti-GFP (Cell
Biolabs, LTV-400) and inserted into pMXs-MGT to replace Mef2c.
2.3. Retrovirus packaging and transduction
PlatE packaging cells were maintained in growth media: DMEM
containing 10% fetal bovine serum (FBS), 50 units/50 μg/ml penicillin/
streptomycin, 1 μg/ml puromycin (Sigma), and 100 μg/ml of blasticidin
S (Life Technologies). One day before transfection, 4–5 × 106 cells were
seeded onto 10 cm dish in growth media without puromycin and
blasticidin. The next day, pMXs-based retroviral vectors were intro-
duced into PlatE cells using lab-prepared Calcium Phosphate (CaP)
transfection reagents. Generally, 20 μg of plasmid DNA were combined
with 440 μl ddH2O and 40 μl 2.5 M CaCl2, and the mixture was added
dropwise to 500 μl of 2× HBS (50 mM HEPES, 280 mM NaCl, 10 mM
KCl, 1.5 mM Na2HPO4, 12 mM glucose, pH 7.10) while vortexing. This
mixture was kept at room temperature for 3 min and then added
dropwise to the PlatE cells. Culture media were changed to fresh
media right before transfection and all reagents used were warmed to
room temperature before mixing. Transfected cells were then
incubated overnight at 37 °C with 5% CO2. Medium was changed the
next day and virus-containing supernatant was collected 48 h after
transfection, ﬁltered through a 0.45 μm cellulose acetate ﬁlter (Thermo
Scientiﬁc) and incubated with PEG8000 (Sigma, 4 volumes of superna-
tant and 1 volume of 40% PEG8000/PBS) overnight at 4 °C. Viruses were
then pelleted by centrifuge at 3500 rpm, 4 °C for 30 min, re-suspended
with ﬁbroblast media (IMDM/20% FBS) supplemented with 4 μg/ml
polybrene (Life Technologies), and added to target cells immediately.
Twenty-four to 48 h after infection, the virus-containing medium was
replaced with iCM medium (10% FBS of DMEM/M199 (4:1)) and
changed every 2–3 days after. For positive selection, puromycin was
added to target cells (4 μg/ml for MEF and 2 μg/ml for CF and TTF)
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concentration of 1 μg/ml.
2.4. Cell culture and isolation of CM, CF and TTF
HL-1 CM cell line was cultured in Claycomb medium supplemented
with 10% fetal bovine serum (FBS), 100 units/100 μg/ml penicillin/strep-
tomycin, 0.1 mM norepinephrine and 2 mM L-glutamine (Sigma).
Primary neonatal CM was isolated by enzyme digestion followed by
negative Magnetic-Activated Cell Sorting (MACS). Brieﬂy, hearts were
removed from P0–P2mice and rinsed and squeezed in chilled PBS to re-
move blood and other tissues. The hearts were then digested in 10 ml
enzyme mix (0.5 mg/ml Collagenase II (Worthington) and 20 U/ml
DNAseI (USB) in PBS) in 37 °C water bath with stirring for 5 × 10 min.
Cells were collected, passed through 40 μm cell strainer and red blood
cells (RBC) were removed by lysing in 1 ml of RBC lysis buffer
(150 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA) for 1 min at room
temperature. The resulting RBC-free cells were resuspended in MACS
buffer (DPBSwith0.5%BSAand 2mMEDTA), counted, and resuspended
with 10 μl negative selection beads (neonatal CM isolation kit, Miltenyl
Biotech) in 90 μl MACS buffer per 10 million cells. After 15 min incuba-
tion at 4 °C, the cell-bead mixture was resuspended with 2 ml MACS
buffer and passed through LS columnprovided in the kit and the column
was washed three times with 1 ml MACS buffer. CMs in the ﬂow
through and wash through was collected, pelleted, and resuspended
in TRIZOL (Invitrogen, for RNA extraction and qRT-PCR), DNAzol
(Invitrogen, for genomic DNA extraction and bisulﬁte sequencing) or
1% paraformaldehyde/PBS (EMS, for ChIP). Isolation of neonatal (day
1.5) explant CF, TTF and fresh CFwas performed as previously described
(Wang et al., 2015).
2.5. MEF preparation
E13.5 αMHC-GFP+ MEFs were prepared as previously described
(Jozefczuk et al., 2012). Brieﬂy, E13.5 embryos were isolated from preg-
nant αMHC-GFP mice. The head and red organs were removed from
each embryo and remainder of the embryo was ﬁnely minced with a
sterile razor blade, digested in 1 ml of 0.05% trypsin/EDTA containing
100 Kunitz units of DNase I for 15 min at 37 °C, then resuspended in
MEFmedium (DMEMcontaining 10% FBS, and 1× penicillin/streptomy-
cin) and plated onto 0.1% gelatin-coated dish. Unattached cells were
removed after 2 h and the attached ﬁbroblasts (P0, passage 0) were
frozen after 24 h of culturing. Each embryo was also genotyped using
the excised red organs and only αMHC-GFP+ MEFs were used for
reprogramming. P3–P5MEFswere predominantly used and the seeding
density was 1 × 104 cells/cm2 for immunoﬂuorescence staining and
3 × 104 cells/cm2 for ChIP.
2.6. Immunoﬂuorescence staining and ﬂow cytometry
For immunoﬂuorescence staining, at day 10 post-transduction, cells
were ﬁxed with 4% paraformaldehyde/PBS at room temperature for
15 min, permeabilized with 0.1% Triton/PBS for 15 min, blocked with
5% BSA for 1 h, then incubated with primary antibody (rabbit α-GFP,
Invitrogen, 1:500 dilution) at 4 °C overnight, secondary antibody
(Alexa Fluor 488-conjugated donkey anti-rabbit IgG, Invitrogen, 1:500
dilution) for 1 h at room temperature, and DAPI nuclei staining in
mounting medium Vectashield (Vector labs). Between each step, the
cells were washed three times with PBS. Images were acquired using
EVOS® FL Auto Cell Imaging System (Life Technologies). For ﬂow
cytometry, cells were ﬁrst dissociated with 0.05% trypsin/EDTA (Life
Technologies) for 5 min at 37 °C and then ﬁxed, permeabilized, and
stained as described above, except that FACS buffer (PBS supplemented
with 2% FBS and 2 mM EDTA) was used for washing in between steps,
the blocking step was omitted, and antibody incubation was done at
4 °C for 30 min. Cells were then run on BD Accuri™ C6 ﬂow cytometer.2.7. ChIP-qPCR
For primary neonatal CM, ChIP was performed using the Magnify
ChIP system (ThermoFisher) according to the manufacturers' instruc-
tions. For all other cells, ChIP was performed as previously described
(Wang et al., 2009). Brieﬂy, 5–10 million cells were cross-linked using
1% paraformaldehyde/PBS at 37 °C for 15 min and sheared using
XL2020 sonicator (MISONIX, intervals 30 s on, 60 s off for 3–6 min).
The chromatin–histone complex was then immunoprecipitated using
rabbit α-H3K4me3/α-H3K27me3/control IgG (Active Motif #39915 &
39155) and Pierce™ Protein A/G UltraLink™ Resin. Eluted chromatin–
histone complexes were then reverse-crosslinked in 0.2 M NaCl by
incubating in 70 °C water bath overnight and the DNA was puriﬁed by
phenol/chloroform extraction followed by ethanol precipitation. DNA
quality/size was checked by agarose gel electrophoresis and qPCR was
performed with SYBR® Green PCR Master Mix (Applied Biosystems)
on ABI ViiA 7 real-time PCR system (Applied Biosystems) as per manu-
facturer protocols. Primers were designed with Primer3 and their
sequences are listed in Table S1. Detailed information of all the tested
genes is listed in Table S2.
2.8. Quantitative RT-PCR (qRT-PCR)
RNA extraction, reverse transcription, and qPCR were performed as
previously described (Wang et al., 2015). Additional primers for SYBR
Green qPCR were designed with Primer3 and their sequences are listed
in Table S3.
2.9. Bisulﬁte sequencing
Cells were harvested at day 3 post-transduction by trypsinization,
and genomic DNA was extracted using DNAzol and bisulﬁte converted
(~500 ng/reaction) using the EZ DNA Methylation-Gold Kit (Zymo Re-
search). Between 1 and 4 μl of the 10 μl bisulﬁte converted DNA was
used for PCR ampliﬁcation of the promoter regions of Myh6 and Nppa
genes using previously described primers (Ieda et al., 2010) and the
GoTaq polymerase (Promega). The PCR productswere then PCR cleaned
up and TA-cloned into pGEMT-easy vector (Promega). Ten to 30 clones
in each sample were picked, cultured, and sequenced.
2.10. Statistical analyses
Where appropriate, values are expressed as the mean ± standard
deviation of triplicate experiments. Statistical analyses were performed
with one-way or two-way analyses of variance followed by Bonferroni
correction. A P value of b0.05 was considered statistically signiﬁcant
(*), a P value of b0.01 was considered highly signiﬁcant (**), and a P
value of b0.001 was considered strongly signiﬁcant (***). All data are
representative of multiple repeated experiments.
3. Results
3.1. H3K27me3 and H3K4me3 at cardiac and ﬁbroblast loci in ﬁbroblasts
and CMs
To understand epigenetic re-patterning along iCM reprogramming,
we ﬁrst determined H3K27me3 and H3K4me3 patterns in ﬁbroblasts
and CMs, the initial and target cell types of iCM reprogramming. Three
different types of primary ﬁbroblasts includingMEF, CF, and TTF, prima-
ry neonatal CMand the CM cell line HL-1were used.We focused on car-
diac genes and ﬁbroblast genes because their respective activation and
inactivation represent the conversion of ﬁbroblast to CM. The cardiac
genes we interrogated included reprogramming factorsM, G, T and car-
diac structural and functional genes. The β-actin-encoding Actb was
used as a negative control for H3K27me3 and as a positive control for
H3K4me3; Hoxa10 and Hoxc10were used as positive controls for both
Fig. 1.H3K27me3 andH3K4me3 at cardiac promoters and promoters ofﬁbroblastmarker genes. H3K27me3 andH3K4me3 ChIPwas performedwith primary neonatal CM, HL-1, MEF, CF,
and TTF cells. Enrichment of cardiac genes (A) and ﬁbroblast marker genes (B) was determined by quantitative PCR using up to ﬁve pairs of primers designed for each gene. For each gene
and each cell type, the fold enrichment of each histonemark to ChIP inputwas plotted against the distance of each primer pair to TSS in kilo bases (Kb). H3K27me3 andH3K4me3 ChIP-seq
peaks from mouse heart (the ENCODE project) and MEF (Koche et al., 2011), based on which the qPCR primers were designed, were shown as reference. Original data can be found in
Supplementary Figs. 1, 2, and 4.
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chromatin 8 (Chr_8) was included as a negative control for both
histone marks. Up to ﬁve pairs of primers were designed for each gene
(Table S1) at locations showingH3K27me3 and H3K4me3 peaks in pre-
viously published ChIP-seq data (Wamstad et al., 2012; Koche et al.,
2011); these peaks usually occur around the transcription start site
(TSS) of the gene (Figs. 1 & 2, ChIP-seq peaks from heart (the ENCODE
database) andMEF (Koche et al., 2011)). Our ChIP-qPCR results demon-
strated thatM, G, and Tweremarked by H3K4me3 only in both primary
CM and HL-1, and by both H3K27me3 and H3K4me3 in ﬁbroblasts ex-
cept for Mef2c, which does not show H3K27me3 peaks in any ChIP-
seq data (Fig. 1A, S1A, B, S2A, B). Interestingly, even though all three
types of ﬁbroblasts were marked by both H3K27me3 and H3K4me3 at
these loci, CFs had the lowest H3K27me3 and highest H3K4me3,
while TTF showed the opposite trend (Fig. 1A, S1A, B, S2A, B). Further
examination of cardiac structural (Tnnt2 and Myh6) and functional
(Ryr2, Nppa and Pln) genes showed that they were marked by
H3K4me3 only in CMs and H3K27me3 only (high levels at Tnnt2 andRyr2 and low levels atMyh6, Nppa and Pln) in ﬁbroblasts (Fig. 1A, S1A,
B, S2C, D). H3K27me3 levels at these loci encoding cardiac structural
and functional genes were slightly lower in CF than MEF and TTF.
We then determined H3K4me3 and H3K27me3 patterns at
ﬁbroblast marker genes. Fibroblasts are heterogeneous in nature, and
a set of markers have been reported for use in the identiﬁcation of
ﬁbroblasts (Krenning et al., 2010; Lajiness and Conway, 2014). Among
them are collagen and related genes (Col1a1, Col1a2, Col3a1 and Lox),
mesenchymal markers (Pdgfra, Postn, Vim and Ddr2), ﬁbroblast growth
factors and their receptors (Fgf17, Fgf20 and Fgfr4), and other markers
(Thy1, Eln and S100a4 that encodes ﬁbroblast-speciﬁc protein 1, FSP1)
(Acharya et al., 2012; Smith et al., 2011; Moore-Morris et al., 2014;
Snider et al., 2009). The majority of these tested genes (Col1a1, Col1a2,
Col3a1, Postn, S100a4, Thy1, Pdgfra and Lox) were marked by
H3K4me3 only in ﬁbroblasts and unmarked in HL-1; some of them
(Thy1, Pdgfra and Lox) were marked by H3K27me3 only in primary
CM while the others were unmarked (Col1a1, Col1a2, Col3a1, Postn,
and S100a4) (Fig. 1B, S1, S3). Interestingly, two well-established
Fig. 2.H3K27me3 andH3K4me3 at loci ofﬁbroblast-enriched TFs. (A)H3K27me3 andH3K4me3 ChIPwas performedwith CM, HL-1,MEF, CF, and TTF cells, followed by qPCRof ﬁbroblast-
enriched TF genes. Plotting is the same as Fig. 1. (B) RNA expression ratio of ﬁbroblast-enriched TFs in freshly isolated neonatal CFs to CMs was determined by qRT-PCR. Tnnt2, a CM
contractility gene, was included as a negative control. Original data can be found in Supplementary Figs. 4, 5 and 6.
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H3K4me3 in primary CM and HL-1. Some of the tested loci (Ddr2,
Fgf17, Fgf20 and Fgfr4) showed high levels of H3K27me3 and/or no
H3K4me3 in ﬁbroblasts and were not followed in reprogramming
experiments outlined below.
3.2. Identiﬁcation of ﬁbroblast-enriched TFs and their H3K27me3 and
H3K4me3 patterns
TFs are a group of genes residing at the top of the transcriptional
hierarchy of the gene regulatory network. TF-mediated cellular
reprogramming (Huang et al., 2011; Ieda et al., 2010; Szabo et al.,
2010; Vierbuchen et al., 2010; Takahashi and Yamanaka, 2006) further
supports their central roles in cell fate determination. We therefore in-
vestigated epigenetic changes at ﬁbroblast TF loci along the cardiac
reprogramming process. We started with identifying a more completelist of ﬁbroblast-enriched TFs. Twomouse transcription factor databases
(TFDB), Animal TFDB and RIKEN TFDB, were combined to generate a
complete list of 3049 mouse TF transcripts. Previously published RNA-
seq data (Giudice et al., 2014) was re-analyzed and expression levels
of 2163 TF transcripts in neonatal CF and CM were acquired (Table S4,
Fig. S4). Twenty-seven TFs were then selected as CF-enriched TFs
based on their high expression in CF and high ratio of CF/CM expression
(Fig. S4). Among them, Tcf21 is a central regulator of CF lineage speciﬁ-
cation during development (Acharya et al., 2012; Braitsch et al., 2012);
Twist1 and Twist2 play essential roles in epithelial-mesenchymal
transition (EMT, (Thiery et al., 2009)); early growth response gene
family (Egr1, 2, 3) is implicated in the pathogenesis of ﬁbrosis
(Bhattacharyya et al., 2011). We then determined H3K27me3 and
H3K4me3 patterns at the promoters of TFs showing peaks in the
above-mentioned ChIP-seq data (Fig. 2A); TFs showing no H3K27me3
peaks from heart tissue (ENCODE, Fig. 2A) were not assessed for
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ChIP-qPCR demonstrated that H3K27me3 and H3K4me3 patterns at
most of these loci were not dramatically different in primary CMs and
ﬁbroblasts (Fig. 2A, S1, S5), which is in great contrast to cardiac loci
and ﬁbroblast marker genes (Fig. 1). Most of the loci tested for
H3K27me3 and H3K4me3 (Tcf21, Egr2, Foxc2, Sox9, Twist1, and Msc)
were shown to be positive for both marks in primary CMs and at least
one subtype of ﬁbroblasts, except that Twist2 and Egr3 were marked
by H3K27me3 only in primary CMs (Fig. 2A). Similarly, the loci tested
for H3K4me3 only (Egr1, Jdp2, Ski, Klf3, Xbp1 and Myc) were marked
by H3K4me3 in both primary CMs and ﬁbroblasts (Fig. 2A). Interesting-
ly for the HL-1 CM cell line, all of the tested loci were unmarked or
marked byminimal levels of H3K27me3 orH3K4me3 (Fig. 2A), suggest-
ing that despite functional similarities of HL-1 to CM, HL-1 cell line
might not have the identical epigenetic states as primary CM and should
be used cautiously in future epigenetic studies. In addition, among the
three types of ﬁbroblasts, CFs showed consistently higher levels of
H3K27me3 at all marked promoters but there seems to be no speciﬁc
pattern for the levels of H3K4me3 among the three ﬁbroblast types.
Tcf21, a key regulator of the CF lineage, was found to be marked by
H3K4me3 in CFs but not in MEFs or TTFs. Consistently, we also found
that Tcf21 is expressed only in CFs but not the other two ﬁbroblast cell
types (data not shown). Comparison of mRNA expression levels of the
selected TFs in freshly isolated neonatal CFs and CMs using qRT-PCR
conﬁrmed their enrichment, ranging from 2.4 to 24 fold, in CFs
(Fig. 2B, S6).
In summary, CMs are marked by H3K4me3 at cardiac marker and
regulatory gene promoters, by H3K27me3 only or unmarked at ﬁbro-
blast marker promoters, and by both H3K27me3 and H3K4me3 at
ﬁbroblast-enriched TFs; ﬁbroblasts aremarked by H3K27me3 at cardiac
marker loci, by H3K4me3 at ﬁbroblast marker loci, and by both
H3K27me3 and H3K4me3 at M, G and T and ﬁbroblast-enriched TFs.
This is consistent with the general notion that regulatory genes, such
as TFs, are subjected to dynamic controls and more likely to be bivalent
than structural/marker genes (Paige et al., 2012; Boyer et al., 2006; Lee
et al., 2006). Based on the above data (Figs. 1, 2), we selected one pair of
primers with the highest enrichment for each gene and each histone
modiﬁcation (Table S1) and continued to investigate how H3K27me3
and H3K4me3 are re-patterned at critical time points during iCM
reprogramming.
3.3. Early re-patterning of H3K27me3 and H3K4me3 at cardiac promoters
during iCM reprogramming
We recently demonstrated that different order combinations of
reprogramming factors in a polycistronic construct give rise to deﬁned
ratios of M, G and T protein expression and differential iCM
reprogramming outcomes (Wang et al., 2015). In the current study,
we chose to focus on the optimal reprogramming construct, MGT, and
compare it in parallel to the least optimal construct, GTM, in order to
determine the epigenetic dynamics during iCM reprogramming and
how they correlate with the reprogramming outcome. To facilitate
this effort, we modiﬁed GTM and control DsRed constructs by adding
a puromycin selection marker to further enrich virus-transduced cells,
in a way similar to our pMXs-puro-MGT construct (Wang et al., 2015).
Transduction of ﬁbroblasts using these new constructs yielded expected
reprogramming efﬁciencies: high with MGT and low with GTM
(Fig. S7). This system combines deﬁned ratios of reprogramming factor
expression, a single retrovirus transduction, and puromycin selection,
thus ensuring desired reprogramming outcomes and a relatively ho-
mogenous cell population. For all of the following experiments, we uti-
lized this system.
M, G, and T-induced conversion of ﬁbroblasts to iCMs is a long
process with deﬁned stages. Cardiac markers such as αMHC-GFP start
to be activated around day 3 and sarcomere structures begin to form
around day 10 (Ieda et al., 2010; Wang et al., 2015). Therefore, wedetermined the levels of H3K27me3, H3K4me3, and mRNA expression
at these two critical time points during iCM reprogramming. We ﬁrst
examined the M, G, and T promoters. ChIP-qPCR results revealed
signiﬁcant decreases in H3K27me3 levels associated with optimal
reprogramming (MGT) starting at day 3, and unaltered H3K4me3
under both reprogramming conditions (MGT and GTM) (Fig. 3A,
exception: no initial H3K27me3 at Mef2c). Further examination of
cardiac structural genes (Tnnt2 andMyh6) and functional genes (Ryr2,
Pln and Nppa) revealed signiﬁcant decreases in H3K27me3 and/or
increases in H3K4me3 (except Nppa) starting day 3, and concomitant
dramatic increases in RNA expression (Fig. 3B). Among them, Tnnt2
showed the most prominent changes compared to other cardiac struc-
tural and functional genes examined, with more than a 3-fold decrease
in H3K27me3, an 18-fold increase in H3K4me3, and a 180-fold increase
in mRNA expression on day 10. While H3K27me3 and H3K4me3 at
Myh6 promoter showed similar trends to those at Tnnt2 locus,
H3K4me3 at Ryr2 and Pln promoters was more greatly affected than
H3K27me3. These changes were observed as early as day 3, continued
to be detected on day 10, and were associated with optimal
reprogramming and transcription activation, except for Nppa (Fig. 3B),
over-activation of which might hinder reprogramming (Wang et al.,
2015). Increased H3K27me3 at Nppa on day 10 under the optimal
reprogramming condition is consistent with its slightly decreased
mRNA levels on day 10 (MGT, Fig. 3B) and also our previous result
that NppamRNA is upregulated to a greater extent under the least opti-
mal reprogramming condition rather than the optimal one (Wang et al.,
2015). Together, our data showed an early re-patterning of H3K27me3
and H3K4me3 at cardiac promoters paralleled by a dramatic increase in
their mRNA expression during iCM induction.
3.4. Later H3K27me3 and H3K4me3 re-patterning at ﬁbroblast promoters
during iCM reprogramming
Efﬁcient and complete erasure of ﬁbroblast signatures is critical for
efﬁcient reprogramming. Early down-regulation of the ﬁbroblast
surface marker THY1 at day 1–2 is required for successful iPSC
reprogramming (Polo et al., 2012). Therefore, we next studied
H3K27me3 and H3K4me3 re-patterning at ﬁbroblast loci encoding
both ﬁbroblast marker genes and ﬁbroblast-enriched TFs. For ﬁbroblast
marker genes, ChIP-qPCR demonstrated decreased H3K4me3 at Col1a2,
Col3a1, and Postn paralleled by a decrease in their mRNA expression
levels starting from day 3 under both reprogramming conditions
(Fig. 4A). On day 10, decreased H3K4me3 was observed at additional
loci (Col1a2, Col3a1, Postn, Eln, and Pdgfra); increased H3K27me3 was
also detected at partially overlapping gene loci, but only under the
optimal reprogramming condition (MGT) (Col3a1, Postn, Eln, Pdgfra,
Thy1, and Lox, Fig. 4A). Quantitative RT-PCR revealed a coordinated
and gradual decrease in mRNA expression of those genes except for
Thy1 (Fig. 4A). Among them, Col1a2, Col3a1, Postn, Eln and Pdgfra tran-
scripts were decreased by 63–93% under the optimal reprogramming
condition at day 10 while Lox was decreased by 35%. PDGFRα is a cell
surface tyrosine kinase receptor that plays an important role in epicar-
dial EMT and CF fate speciﬁcation (Smith et al., 2011); Lox encodes an
enzyme for crosslinking collagen and elastin precursors and is essential
for the formation of collagen and elastin ﬁbers (Hamalainen et al.,
1991). Decreased mRNA levels of Eln, Pdgfra and Lox on day 3 preceded
changes in their H3K27me3 and/or H3K4me3 levels on day 10, suggest-
ing the involvement of other regulatorymechanisms for their transcrip-
tion. It is also possible that following transcription repression, histones
were further modiﬁed to “lock” the expression pattern of these loci.
Similarly, H3K27me3 and H3K4me3 at Col1a1 were unchanged, but
Col1a1 mRNA expression was decreased, suggesting the presence of
other regulatory mechanisms. Interestingly, increased H3K27me3 on
day 10 at Thy1 did not lead to changes in Thy1 mRNA expression
under the optimal reprogramming condition. Noticeably, Vim and the
FSP1-encoding gene S100a4 did not show the expected histone mark
Fig. 3.Re-patterning ofH3K27me3 andH3K4me3at cardiac loci during iCM reprogramming.H3K27me3 andH3K4me3ChIP of iCMs generated under the optimal condition (MGT) and the
least optimal one (GTM) were performed on day 3 and day 10, followed by qPCR of M, G, T (A) or cardiac structural and marker genes (B). DsRed: retroviral transduction control. RNA
expression levels of these genes were also determined in parallel by qRT-PCR and normalized to Actb ﬁrst and then to the DsRed control.
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However, this is consistent with Vim's high level of H3K4me3 in CMs
(Fig. 1B) and growing evidence indicating that FSP1 is not as speciﬁc
for ﬁbroblast as its name suggests (Kong et al., 2013). These results
support the idea that VIM and FSP1 should be used cautiously as
ﬁbroblast markers in the future. Taken together, our data showed
delayed re-patterning of H3K27me3 and H3K4me3 at ﬁbroblast marker
promoters during iCM reprogramming, accompanied by a gradual
decrease in corresponding mRNA expression.
Next, we determined theH3K4me3 andH3K27me3 dynamics at loci
encoding ﬁbroblast-enriched TF genes. With ChIP-qPCR, we found
signiﬁcantly increased H3K27me3 at about one-third of the tested
promoters (Tcf21, Egr2 Sox9, Foxc2, and Egr3) under the optimal
reprogramming condition (MGT) on day 10 but not day 3 (Fig. 4B).
However, H3K4me3 was not decreased at these genes, except at Egr2,
on day 10 (Fig. 4B). Gene expression analysis by qRT-PCR revealed
decreased mRNA levels of Egr2, Sox9, Egr3, Twist1, and Twist2 under
the optimal reprogramming condition starting from day 3 (Fig. 4B).
On day 10, the mRNA levels of these genes were decreased by 62–86%.
Egr2 and Egr3, members of the early growth response family, have
been demonstrated to be downstream targets of TGF-β signaling and
to mediate pro-ﬁbrotic responses (Fang et al., 2011; Fang et al., 2013).
Sox9, a sex-determining region Y (SRY)-related TF, has been shown pre-
viously to induce neural crest EMT and to mediate PDGFR-dependent
epicardium EMT (Smith et al., 2011; Sakai et al., 2006). Twist1 and
Twist2 are both well-known as central regulators of EMT (Thiery et al.,
2009). Interestingly, H3K27me3 and/or H3K4me3 at some loci were
unchanged under the optimal condition (Twist1, Twist2, Egr1, Jdp2, Ski
and Klf3), but their mRNA expression was decreased, suggesting the
presence of other regulatory mechanisms. H3K27me3 deposition onday 10 at Tcf21 and Foxc2 did not lead to changes in their mRNA expres-
sion under the optimal condition, but it is possible that these epigenetic
changes have potential long-term impact on complete erasure of ﬁbro-
blast signatures and eventual successful reprogramming that is not
reﬂected by their gene expression level at the time of detection here.
Some of the tested ﬁbroblast-enriched TFs did not show histone mark
or gene expression changes (Msc, Xbp1 andMyc), suggesting that they
may play minor or no roles in direct cardiac reprogramming; they
were selected based on high ratio of CF/CM expression and high CF ex-
pression, but a high expression level in CF may not guarantee a key reg-
ulatory role in ﬁbroblast/cardiac fate determination. Taken together, our
data showed a late increase of H3K27me3 at a subset of ﬁbroblast-
enriched TFs during reprogramming, and Egr2, Egr3, Sox9, Twist1 and
Twist2 showed decreased mRNA expression.
In summary, the results above revealed a re-patterning of
H3K27me3 and H3K4me3 during iCM reprogramming. Overall, cardiac
loci lost H3K27me3 and gained H3K4me3 as early as day 3 during iCM
generation; ﬁbroblast loci gradually lost H3K4me3 and eventually
gained H3K27me3 in this process. Our data are suggestive of early
rapid activation of the cardiac program, and later progressive suppres-
sion of ﬁbroblast fate.
3.5. Demethylation of cardiac gene promoters during iCM reprogramming
DNAmethylation is another important layer of epigenetic regulation
in addition to histonemodiﬁcations. Therefore, we investigated wheth-
er and how DNA methylation re-patterns at cardiac promoters during
iCM reprogramming. The Myh6 and Nppa promoters have been previ-
ously shown to be demethylated in αMHC-GFP+ iCMs at week 4
(Ieda et al., 2010). Our results above showed dramatic increases in
Fig. 4. Re-patterning of H3K27me3 and H3K4me3 at ﬁbroblast loci during iCM reprogramming. H3K27me3 andH3K4me3 ChIP of iCMs generated under the optimal condition (MGT) and
the least optimal one (GTM) were performed on day 3 and day 10, followed by qPCR of ﬁbroblast marker genes (A) or ﬁbroblast-enriched TF genes (B). DsRed: retroviral transduction
control. RNA expression levels of these genes were also determined in parallel by qRT-PCR and normalized to Actb ﬁrst and then to the DsRed control.
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H3K4me3 and H3K27me3 at their promoters were relatively low. So
we chose Myh6 and Nppa and further characterized their methylation
states in the promoters at day 3 of iCM reprogramming using our poly-
cistronic system. Bisulﬁte sequencing showed that theMyh6 promoter
is unmethylated in HL-1 cells, about half-methylated in primary CMs
and heavily methylated in CFs (HL-1, CM and CF-DsRed, Fig. 5A). The
Nppa promoter is unmethylated in HL-1 and primary CMs and about
half-methylated in CFs (HL-1, CM and CF-DsRed, Fig. 5B). Upon intro-
duction of reprogramming factors (MGT or GTM), each promoter was
demethylated at day 3 to a similar extent when we calculated the
total methylation % of all CpGs (10% decrease in methylation forMyh6and about 5% decrease for Nppa by MGT/GTM compared to DsRed,
Fig. 5A, B). These results were consistent with the activation of Myh6
and Nppa during reprogramming, but failed to reﬂect the differential
gene activation capabilities of the two reprogramming conditions
(Fig. 5C, D). So we took a further step to calculate methylation % at
each CpG. We found that certain CpGs were more demethylated
under the optimal reprogramming condition. At the Myh6 promoter,
CpG 3was demethylated by 40% under the optimal condition compared
to DsRed control, while demethylation by 10% occurred under the least
optimal condition (Fig. 5E, G). Interestingly, CpG 3 in theMyh6 promot-
er is also the least methylated CpG in primary CMs, and its methylation
% is the same in primary CM and iCM under the optimal condition (CM
Fig. 5.Demethylation of cardiac gene promoters during iCM reprogramming. Bisulﬁte sequencing of iCMs generated under the optimal condition (MGT) and the least optimal one (GTM)
were performed on day 3. DNAmethylation states atMyh6 (A, E, G) andNppa (B, F, H) promoterswere determined. RNA expression levels ofMyh6 (C) andNppa (D)were also determined
byqRT-PCR. (A, B)Methylation states of all 4 (Myh6) or 11 (Nppa) CpGs in the promoters from ten representative clones. Numbers indicate totalmethylation % combining all clones and all
CpGs. (E, F) Methylation % of individual CpGs. (G, H) Methylation % of main contributing CpGs. HL-1 and primary CM: CM controls. DsRed: retroviral transduction control.
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demethylated under the least optimal condition than under the optimal
one (30% demethylation vs. 20%, Fig. 5F, H). Quantitative RT-PCR
showed that mRNA expression ofMyh6 was more activated under the
optimal condition while expression of Nppa was more activated under
the least optimal condition (Fig. 5C, D). Combined with these results,
our data suggest potentially more important roles for CpG 3 in Myh6
and for CpGs 5 and 6 in Nppa than other CpGs, in regulating the expres-
sion ofMyh6 and Nppa during iCM reprogramming. Together, we show
that promoters of cardiac genesMyh6 and Nppawere demethylated as
early as day 3 during iCM reprogramming. Moreover, the methylation
states of certain deﬁned CpGs at these loci correlated to alterations in
their gene expression during reprogramming, suggesting that these
CpGs might be the major contributing CpGs to transcription regulation
during this process.
4. Discussion
Since the initial report of iCM reprogramming in vitro (Ieda et al.,
2010) and in vivo (Inagawa et al., 2012; Qian et al., 2012; Song et al.,
2012), there have been considerable efforts to enhance the efﬁciency
of direct cardiac reprogramming. One of the strategies is to optimize
reprogramming efﬁciency through identifying enhancers of iCM gener-
ation or new combinations of reprogramming cocktails. Jayawardena
et al. reported iCM induction using a microRNA cocktail consisting of
miR-1, -133, -208, and -499 (Jayawardena et al., 2012). Others found
that different TF/microRNA combinations could efﬁciently generate
iCMs depending on the starting ﬁbroblast type, the viral-delivery sys-
tem and the cardiac reporter(s) being used. These various combinations
of reprogramming factors include wild-type G, T,Hand2 in combination
withMef2c fused with the transactivation domain ofMyoD (Hirai et al.,
2013), the combination of M, T, and Myocd (Protze et al., 2012), the
combination of G, M, T, Hand2, and Nkx2.5 (Addis et al., 2013), the
combination of G, M, T,Myocd, and Srf (Christoforou et al., 2013), and
the G, M, T cocktail in combination with miR-1 or miR-133 (Muraokaet al., 2014). Additionally, growth factors and small molecules have
been used to enhance the efﬁciency of iCM reprogramming. Pre-
conditioning infarcted hearts with VEGF and inhibition of TGFβ signal-
ing has been shown to improve cardiac reprogramming (Ifkovits et al.,
2014; Mathison et al., 2012). Furthermore, we recently demonstrated
that stoichiometry of G, M, T could greatly affect iCM reprogramming
and a relative high level of M and moderate levels of G and T in a MGT
polycistronic construct gave rise to enhanced reprogramming (Wang
et al., 2015). During the review process of our manuscript, two studies
were published, reporting enhanced reprogramming efﬁciency based
on the G, M, T and Hand2 cocktail by overexpression of the protein ki-
nase Akt1 (Zhou et al., 2015) or by suppression of pro-ﬁbrotic signaling
such as TGFβ or ROCK kinase pathways with small molecule inhibitors
(Zhao et al., 2015). Nevertheless, how the ﬁbroblast epigenome is
reset during direct cardiac reprogramming remains largely unknown.
Ieda et al. examined the epigenetic states of three cardiac promoters
(Tnnt2, Ryr2 and Actn2) in 4-week FACS-sorted αMHC-GFP+ iCMs.
ChIP –qPCR analysis revealed decreased H3K27me3 and increased
H3K4me3 at these three promoters in late-stage reprogrammed cells.
However, epigenetic re-patterning has been shown to occur rapidly
after the overexpression of reprogramming factors, for example, within
a few days for iPSCs (Papp and Plath, 2013; Koche et al., 2011).
In this study, we intended to characterize early epigenetic changes
when the cell fate transitionwas initiated. Therefore, we took advantage
of our puro-selectable polycistronic system to enrich cells that have
taken up all reprogramming factors, and determined the epigenetic re-
setting at two critical time points at early stages of iCM reprogramming
(day 3 and day 10). In addition, in order to gain insights into how ﬁbro-
blast fate is suppressed during iCM reprogramming, we also expanded
the testing loci to include both cardiac promoters and ﬁbroblast
promoters; particularly some largely unexplored ﬁbroblast regulatory
genes in other iCM studies. As critical control experiments, we charac-
terized H3K27me3 and H3K4me3 patterns at cardiac and ﬁbroblast
loci in CMs and ﬁbroblasts. Our results revealed that in addition to
cardiac regulatory genes, ﬁbroblast regulatory gene promoters were
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ing the plasticity of ﬁbroblasts. Analysis of H3K27me3 and H3K4me3
dynamics during iCM reprogramming revealed early re-patterning of
H3K27me3 and H3K4me3 at cardiac loci and later alterations at
ﬁbroblast loci paralleled by a dramatic increase in cardiac markers
expression and a gradual decrease in ﬁbroblast markers expression.
These results suggest an early activation of the cardiac program and a
progressive suppression of ﬁbroblast fate. Additionally, speciﬁc
CpGs in the promoters of Myh6 and Nppa were found to be
possible main contributors to total CpG demethylation during iCM
reprogramming and their methylation states were correlated with
transcriptional activation of Myh6 and Nppa. The methylation states of
these CpGs might have important regulatory roles that contribute to
the control of DNA accessibility of these two loci during iCM
reprogramming. Our study thus reveals a differential re-patterning of
H3K27me3, H3K4me3 at cardiac and ﬁbroblast loci, and establishes
the platform and conditions that may be used in future genome-wide
studies.
To the best of our knowledge, this is the ﬁrst study to characterize
H3K27me3 and H3K4me3 re-patterning accompanying cardiac
reprogramming. Recently, it was reported that iPSC reprogramming is
characterized by global loss of H3K27me3 in the beginning and later
restoration of H3K27me3 at selected sites (Hussein et al., 2014). Here
we observed loss of H3K27me3 at cardiac genes early (day 3) in iCM
reprogramming (Fig. 3). However, whether the observed removal of
H3K27me3 is speciﬁc to the cardiac lineage remains to be answered.
In iPSC reprogramming, early down-regulation (at day 1–2) of ﬁbro-
blast markers such as THY1 is one of the hallmarks and prerequisites
for reprogramming to proceed (Polo et al., 2012). Here in iCM
reprogramming, we showed that H3K27me3 deposition at ﬁbroblast
genes was only observed on day 10 and corresponding mRNA expres-
sion gradually decreased over time (Fig. 4). More interestingly, Thy1 ex-
pression was not completely repressed even at day 10 during iCM
reprogramming (Fig. 4A), suggesting that even though both iPSC and
iCM reprogramming start from ﬁbroblasts, the routes to pluripotency
and to iCM might be different. The difference may reﬂect differential
mechanisms in how the reprogramming factors inﬂuence the regula-
tion of histone and DNA modiﬁcation, or it may suggest that direct
cardiac reprogramming allows co-existence of cardiac and certain
ﬁbroblast signatures during the early phase of reprogramming. A recent
report showed that suppression of pro-ﬁbrotic signaling with small
molecule inhibitors led to increased efﬁciency and accelerated kinetics
of iCM reprogramming (Zhao et al., 2015). Yet, future studies of cell
reprogramming including iCM reprogramming are required in order
to address the necessity and mechanisms of erasure of the ﬁbroblast
program, which may provide novel insights for acceleration and im-
proved completeness of the reprogramming process. What's more, to
completely understand epigenetic landscape dynamics during cardiac
reprogramming and how such changes orchestrate the cell fate conver-
sion, genome-widemapping of a complete set of histonemarks is need-
ed in the future.
From induced pluripotency to the generation of iCM, iNeuron,
iHepatocytes and induced multilineage blood progenitors, ﬁbroblasts
have often been chosen as the starting cells for reprogramming
(Huang et al., 2011; Ieda et al., 2010; Szabo et al., 2010; Vierbuchen
et al., 2010). The rationale behind this choice of starting cell includes
easy access to ﬁbroblasts compared with other cell types yet other rea-
sons may apply as well. Studies of ESCs revealed that regulatory genes
controlling diverse cell fates were largely marked by both H3K27me3
and H3K4me3 in pluripotent cells, which denotes “poising” of these
genes for rapid activation or silencing upon differentiation (Bernstein
et al., 2006). Depending on the developmental course, these “bivalent”
genes resolve to either only H3K4me3-marked or only H3K27me3-
marked in terminally differentiated cells (Mikkelsen et al., 2007). Our
data here reveal exclusive marking of cardiac regulatory genes (M, G
and T) by H3K4me3 and marking of ﬁbroblast-enriched TFs by bothH3K27me3 and H3K4me3 in CMs (Figs. 1, 2). Interestingly, all three
types of primary ﬁbroblasts MEF, CF, and TTF were marked by both
H3K27me3 and H3K4me3 at cardiac TFs (M, G and T) and at
ﬁbroblast-enriched TFs (Figs. 1, 2), similar to ﬁndings in ESCs
(Wamstad et al., 2012). Our data imply the possibility that ﬁbroblasts
are more amenable to being reprogrammed compared to other somatic
cell types because of their lower epigenetic barriers and thus higher
plasticity. Parallel studies comparing epigenetic re-patterning during
cellular reprogramming starting from ﬁbroblasts and other cell types
are needed to evaluate this possibility.
Even though all ﬁbroblasts are categorized as such, different types of
ﬁbroblasts could have distinct origins, functions, gene expression pro-
ﬁles and epigenetic patterns (Sorrell et al., 2004; Baum and Duffy,
2011; Rodemann, 2011). Our ChIP-qPCR results showed that
H3K27me3/H3K4me3 states (positive or negative) in the three tested
ﬁbroblasts CF, MEF, and TTF were mostly consistent across cardiac and
ﬁbroblast loci with a few exceptions, but the levels of methylation
were different. At certain cardiac genes, CF has higher H3K4me3
(Mef2c, Gata4) and lower H3K27me3 (Gata4, Tnnt2, Ryr2) compared
to MEF and TTF while TTF has higher H3K27me3 and lower
H3K4me3 at Tbx5 compared to CF and MEF (Fig. 1A). At ﬁbroblast-
enriched TF loci, CF generally shows higher H3K27me3 than MEF and
TTF (Fig. 2A). In summary, the H3K27me3/H3K4me3 states in CFs
most resemble those found in primary CMs while the H3K27me3/
H3K4me3 states in TTFs are least similar to CMs among the three. Inter-
estingly, these ﬁndings on epigenetic states of CF, MEF and TTF echo the
reprogramming efﬁciencies from the three ﬁbroblasts. Flow cytometry
and immunoﬂuorescence staining demonstrated that CFs led to the
highest percentage of αMHC-GFP+ cells among the three ﬁbroblasts
while TTFs showed the lowest (Fig. S7). Together, our data suggest
that epigenetic states of the starting ﬁbroblast cells determine the
permissiveness of cardiac fate acquisition in these cells.
Most of the observed H3K27me3 and H3K4me3 re-patterning and
mRNA expression changes of cardiac genes were associated with the
optimal reprogramming condition (MGT, Fig. 3). On the other hand,
H3K27me3 deposition at ﬁbroblast genes was observed mostly under
the optimal reprogramming condition, while H3K4me3 and expression
changes were found under both reprogramming conditions (MGT and
GTM, Fig. 4). Reprogramming factors have been previously shown to in-
teract with chromatin modiﬁers and regulate epigenetic modiﬁcations
during iPSC reprogramming (Buganim et al., 2013; Papp and Plath,
2013; Mansour et al., 2012). As central regulators of the cardiac fate
during development, MEF2C, GATA4, and TBX5 directly bind to and
activate the expression of target genes. In addition, they interact with
various chromatin regulators and contribute to epigenetic remodeling
in a variety of developmental processes including cardiac development
andmorphogenesis (He et al., 2012b; Zhang et al., 2002; Vallaster et al.,
2012). Future studies are needed to clarify the relationships betweenM,
G, T binding, epigenetic re-patterning, and transcription activation of
cardiac genes during iCM reprogramming. Similarly, it remains to be
answered how M, G, T, and their different protein expression levels in
MGT and GTM affect epigenetic remodeling at ﬁbroblast genes during
cardiac reprogramming and contribute to the removal of ﬁbroblast
signatures.
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doi.org/10.1016/j.scr.2016.02.037.Author contributions
Ziqing Liu: conception and design, collection of data, data analysis
and interpretation and manuscript writing; Olivia Chen: collection of
data and manuscript writing; Michael Zheng, Li Wang and Yang Zhou:
collection of data; Chaoying Yin: collection of data and administrative
support; Jiandong Liu: data analysis and interpretation, supervision,
ﬁnancial support; Li Qian: conception and design, data interpretation,
517Z. Liu et al. / Stem Cell Research 16 (2016) 507–518supervision, ﬁnancial support, administrative support, manuscript
writing and ﬁnal approval of manuscript.
Disclosure of potential conﬂicts of interest
None.
Acknowledgments
We thankDr. GregWang for providing the ChIP protocol and helping
set up the ChIP experiment. We thank Yi Yao for help on data analysis
and heatmap generation.We are grateful for expert technical assistance
from the UNC Flow Cytometry Core and UNC Microscopy Core. We
thank members of the Qian lab and the Liu lab for helpful discussions
and critical reviews of the manuscript. This study was supported by
the NIH/NHLBI R00 HL109079 grant to Dr. Liu and the American Heart
Association (AHA) Scientist Development Grant 13SDG17060010 and
the Ellison Medical Foundation (EMF) New Scholar Grant AG-NS-
1064-13 to Dr. Qian.
References
Acharya, A., Baek, S.T., Huang, G., et al., 2012. The bHLH transcription factor Tcf21 is re-
quired for lineage-speciﬁc EMT of cardiac ﬁbroblast progenitors. Development 139,
2139–2149.
Addis, R.C., Ifkovits, J.L., Pinto, F., et al., 2013. Optimization of direct ﬁbroblast
reprogramming to cardiomyocytes using calcium activity as a functional measure
of success. J. Mol. Cell. Cardiol. 60, 97–106.
Baum, J., Duffy, H.S., 2011. Fibroblasts and myoﬁbroblasts: what are we talking about?
J. Cardiovasc. Pharmacol. 57, 376–379.
Bernstein, B.E., Meissner, A., Lander, E.S., 2007. The mammalian epigenome. Cell 128,
669–681.
Bernstein, B.E., Mikkelsen, T.S., Xie, X., et al., 2006. A bivalent chromatin structure marks
key developmental genes in embryonic stem cells. Cell 125, 315–326.
Bhattacharyya, S., Wu, M., Fang, F., et al., 2011. Early growth response transcription fac-
tors: key mediators of ﬁbrosis and novel targets for anti-ﬁbrotic therapy. Matrix
Biol. 30, 235–242.
Boyer, L.A., Plath, K., Zeitlinger, J., et al., 2006. Polycomb complexes repress developmental
regulators in murine embryonic stem cells. Nature 441, 349–353.
Braitsch, C.M., Combs, M.D., Quaggin, S.E., et al., 2012. Pod1/Tcf21 is regulated by retinoic
acid signaling and inhibits differentiation of epicardium-derived cells into smooth
muscle in the developing heart. Dev. Biol. 368, 345–357.
Buganim, Y., Faddah, D.A., Jaenisch, R., 2013. Mechanisms and models of somatic cell
reprogramming. Nat. Rev. Genet. 14, 427–439.
Christoforou, N., Chellappan, M., Adler, A.F., et al., 2013. Transcription factors MYOCD, SRF,
Mesp1 and SMARCD3 enhance the cardio-inducing effect of GATA4, TBX5, and
MEF2C during direct cellular reprogramming. PLoS One 8, e63577.
Delgado-Olguin, P., Huang, Y., Li, X., et al., 2012. Epigenetic repression of cardiac progen-
itor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat.
Genet. 44, 343–347.
Fang, F., Ooka, K., Bhattacharyya, S., et al., 2011. The early growth response gene Egr2
(Alias Krox20) is a novel transcriptional target of transforming growth factor-beta
that is up-regulated in systemic sclerosis and mediates proﬁbrotic responses. Am.
J. Pathol. 178, 2077–2090.
Fang, F., Shangguan, A.J., Kelly, K., et al., 2013. Early growth response 3 (Egr-3) is induced
by transforming growth factor-beta and regulates ﬁbrogenic responses. Am. J. Pathol.
183, 1197–1208.
Feldman, N., Gerson, A., Fang, J., et al., 2006. G9a-mediated irreversible epigenetic inacti-
vation of Oct-3/4 during early embryogenesis. Nat. Cell Biol. 8, 188–194.
Gilsbach, R., Preissl, S., Gruning, B.A., et al., 2014. Dynamic DNA methylation orchestrates
cardiomyocyte development, maturation and disease. Nat. Commun. 5, 5288.
Giudice, J., Xia, Z., Wang, E.T., et al., 2014. Alternative splicing regulates vesicular trafﬁck-
ing genes in cardiomyocytes during postnatal heart development. Nat. Commun. 5,
3603.
Hamalainen, E.R., Jones, T.A., Sheer, D., et al., 1991. Molecular cloning of human lysyl
oxidase and assignment of the gene to chromosome 5q23.3–31.2. Genomics 11,
508–516.
He, A., Ma, Q., Cao, J., et al., 2012a. Polycomb repressive complex 2 regulates normal
development of the mouse heart. Circ. Res. 110, 406–415.
He, A., Shen, X., Ma, Q., et al., 2012b. PRC2 directly methylates GATA4 and represses its
transcriptional activity. Genes Dev. 26, 37–42.
Hirai, H., Katoku-Kikyo, N., Keirstead, S.A., et al., 2013. Accelerated direct reprogramming
of ﬁbroblasts into cardiomyocyte-like cells with the MyoD transactivation domain.
Cardiovasc. Res. 100, 105–113.
Huang, P., He, Z., Ji, S., et al., 2011. Induction of functional hepatocyte-like cells from
mouse ﬁbroblasts by deﬁned factors. Nature 475, 386–389.
Hussein, S.M., Puri, M.C., Tonge, P.D., et al., 2014. Genome-wide characterization of the
routes to pluripotency. Nature 516, 198–206.Ieda, M., Fu, J.D., Delgado-Olguin, P., et al., 2010. Direct reprogramming of ﬁbroblasts into
functional cardiomyocytes by deﬁned factors. Cell 142, 375–386.
Ifkovits, J.L., Addis, R.C., Epstein, J.A., et al., 2014. Inhibition of TGFbeta signaling increases
direct conversion of ﬁbroblasts to induced cardiomyocytes. PLoS One 9, e89678.
Inagawa, K., Miyamoto, K., Yamakawa, H., et al., 2012. Induction of cardiomyocyte-like
cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ. Res. 111,
1147–1156.
Jackson, M., Krassowska, A., Gilbert, N., et al., 2004. Severe global DNA hypomethylation
blocks differentiation and induces histone hyperacetylation in embryonic stem
cells. Mol. Cell. Biol. 24, 8862–8871.
Jayawardena, T.M., Egemnazarov, B., Finch, E.A., et al., 2012. MicroRNA-mediated in vitro
and in vivo direct reprogramming of cardiac ﬁbroblasts to cardiomyocytes. Circ. Res.
110, 1465–1473.
Jozefczuk, J., Drews, K., Adjaye, J., 2012. Preparation of mouse embryonic ﬁbroblast cells
suitable for culturing human embryonic and induced pluripotent stem cells. J. Vis.
Exp. 64, e3854.
Koche, R.P., Smith, Z.D., Adli, M., et al., 2011. Reprogramming factor expression initiates
widespread targeted chromatin remodeling. Cell Stem Cell 8, 96–105.
Kong, P., Christia, P., Saxena, A., et al., 2013. Lack of speciﬁcity of ﬁbroblast-speciﬁc protein
1 in cardiac remodeling and ﬁbrosis. Am. J. Physiol. Heart Circ. Physiol. 305,
H1363–H1372.
Krenning, G., Zeisberg, E.M., Kalluri, R., 2010. The origin of ﬁbroblasts and mechanism of
cardiac ﬁbrosis. J. Cell. Physiol. 225, 631–637.
Lajiness, J.D., Conway, S.J., 2014. Origin, development, and differentiation of cardiac ﬁbro-
blasts. J. Mol. Cell. Cardiol. 70, 2–8.
Lee, T.I., Jenner, R.G., Boyer, L.A., et al., 2006. Control of developmental regulators by
polycomb in human embryonic stem cells. Cell 125, 301–313.
Mansour, A.A., Gafni, O., Weinberger, L., et al., 2012. The H3K27 demethylase utx regulates
somatic and germ cell epigenetic reprogramming. Nature 488, 409–413.
Mathison, M., Gersch, R.P., Nasser, A., et al., 2012. In vivo cardiac cellular reprogramming
efﬁcacy is enhanced by angiogenic preconditioning of the infarctedmyocardiumwith
vascular endothelial growth factor. J. Am. Heart Assoc. 1, e005652.
Mikkelsen, T.S., Ku, M., Jaffe, D.B., et al., 2007. Genome-wide maps of chromatin state in
pluripotent and lineage-committed cells. Nature 448, 553–560.
Moore-Morris, T., Guimaraes-Camboa, N., Banerjee, I., et al., 2014. Resident ﬁbroblast lin-
eages mediate pressure overload-induced cardiac ﬁbrosis. J. Clin. Invest. 124,
2921–2934.
Muraoka, N., Yamakawa, H., Miyamoto, K., et al., 2014. MiR-133 promotes cardiac
reprogramming by directly repressing Snai1 and silencing ﬁbroblast signatures.
EMBO J. 33, 1565–1581.
Nam, Y.J., Lubczyk, C., Bhakta, M., et al., 2014. Induction of diverse cardiac cell types by
reprogramming ﬁbroblasts with cardiac transcription factors. Development 141,
4267–4278.
Ng, S.B., Bigham, A.W., Buckingham, K.J., et al., 2010. Exome sequencing identiﬁes MLL2
mutations as a cause of Kabuki syndrome. Nat. Genet. 42, 790–793.
Paige, S.L., Thomas, S., Stoick-Cooper, C.L., et al., 2012. A temporal chromatin signature in
human embryonic stem cells identiﬁes regulators of cardiac development. Cell 151,
221–232.
Papp, B., Plath, K., 2013. Epigenetics of reprogramming to induced pluripotency. Cell 152,
1324–1343.
Polo, J.M., Anderssen, E., Walsh, R.M., et al., 2012. Amolecular roadmap of reprogramming
somatic cells into iPS cells. Cell 151, 1617–1632.
Protze, S., Khattak, S., Poulet, C., et al., 2012. A new approach to transcription factor
screening for reprogramming of ﬁbroblasts to cardiomyocyte-like cells. J. Mol. Cell.
Cardiol. 53, 323–332.
Qian, L., Berry, E.C., Fu, J.D., et al., 2013. Reprogramming of mouse ﬁbroblasts into
cardiomyocyte-like cells in vitro. Nat. Protoc. 8, 1204–1215.
Qian, L., Huang, Y., Spencer, C.I., et al., 2012. In vivo reprogramming of murine cardiac
ﬁbroblasts into induced cardiomyocytes. Nature 485, 593–598.
Reddington, J.P., Perricone, S.M., Nestor, C.E., et al., 2013. Redistribution of H3K27me3
upon DNA hypomethylation results in de-repression of polycomb target genes.
Genome Biol. 14, R25.
Rodemann, H.P., Rennekampff, H., 2011. Functional diversity of ﬁbroblasts. In: Mueller,
M.M., Fusenig, N.E. (Eds.), Tumor-Associated Fibroblasts and Their Matrix, pp. 23–36.
Sakai, D., Suzuki, T., Osumi, N., et al., 2006. Cooperative action of Sox9, Snail2 and PKA
signaling in early neural crest development. Development 133, 1323–1333.
Smith, C.L., Baek, S.T., Sung, C.Y., et al., 2011. Epicardial-derived cell epithelial-to-
mesenchymal transition and fate speciﬁcation require PDGF receptor signaling. Circ.
Res. 108, e15–e26.
Snider, P., Standley, K.N., Wang, J., et al., 2009. Origin of cardiac ﬁbroblasts and the role of
periostin. Circ. Res. 105, 934–947.
Song, K., Nam, Y.J., Luo, X., et al., 2012. Heart repair by reprogramming non-myocytes
with cardiac transcription factors. Nature 485, 599–604.
Sorrell, J.M., Baber, M.A., Caplan, A.I., 2004. Site-matched papillary and reticular human
dermal ﬁbroblasts differ in their release of speciﬁc growth factors/cytokines and in
their interaction with keratinocytes. J. Cell. Physiol. 200, 134–145.
Suzuki, M.M., Bird, A., 2008. DNA methylation landscapes: provocative insights from
epigenomics. Nat. Rev. Genet. 9, 465–476.
Szabo, E., Rampalli, S., Risueno, R.M., et al., 2010. Direct conversion of human ﬁbroblasts to
multilineage blood progenitors. Nature 468, 521–526.
Takahashi, K., Yamanaka, S., 2006. Induction of pluripotent stem cells frommouse embry-
onic and adult ﬁbroblast cultures by deﬁned factors. Cell 126, 663–676.
Theunissen, T.W., Jaenisch, R., 2014. Molecular control of induced pluripotency. Cell Stem
Cell 14, 720–734.
Thiery, J.P., Acloque, H., Huang, R.Y., et al., 2009. Epithelial-mesenchymal transitions in
development and disease. Cell 139, 871–890.
518 Z. Liu et al. / Stem Cell Research 16 (2016) 507–518Vallaster, M., Vallaster, C.D., Wu, S.M., 2012. Epigenetic mechanisms in cardiac develop-
ment and disease. Acta Biochim. Biophys. Sin. 44, 92–102.
Vierbuchen, T., Ostermeier, A., Pang, Z.P., et al., 2010. Direct conversion of ﬁbroblasts to
functional neurons by deﬁned factors. Nature 463, 1035–1041.
Wamstad, J.A., Alexander, J.M., Truty, R.M., et al., 2012. Dynamic and coordinated
epigenetic regulation of developmental transitions in the cardiac lineage. Cell 151,
206–220.
Wang, G.G., Song, J., Wang, Z., et al., 2009. Haematopoietic malignancies caused by
dysregulation of a chromatin-binding PHD ﬁnger. Nature 459, 847–851.
Wang, L., Liu, Z., Yin, C., et al., 2015. Stoichiometry of Gata4, Mef2c, and Tbx5 inﬂuences
the efﬁciency and quality of induced cardiac myocyte reprogramming. Circ. Res.
116, 237–244.Zhang, C.L., McKinsey, T.A., Chang, S., et al., 2002. Class II histone deacetylases act as
signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488.
Zhao, Y., Londono, P., Cao, Y., et al., 2015. High-efﬁciency reprogramming of ﬁbroblasts
into cardiomyocytes requires suppression of pro-ﬁbrotic signalling. Nat. Commun.
6, 8243.
Zhou, H., Dickson, M.E., Kim, M.S., et al., 2015. Akt1/protein kinase B enhances transcrip-
tional reprogramming of ﬁbroblasts to functional cardiomyocytes. Proc. Natl. Acad.
Sci. U. S. A. 112, 11864–11869.
Zhou, V.W., Goren, A., Bernstein, B.E., 2011. Charting histone modiﬁcations and the
functional organization of mammalian genomes. Nat. Rev. Genet. 12, 7–18.
